# Monitoring and Follow-Up of Patients on Vitamin K Antagonist Oral Anticoagulant Therapy Using Artificial Intelligence: The AIto-Control Project

**Authors:** Adolfo Romero-Arana, Nerea Romero-Sibajas, Elena Arroyo-Bello, Adolfo Romero-Ruiz, Juan Gómez-Salgado

PMC · DOI: 10.3390/jcm14207191 · Journal of Clinical Medicine · 2025-10-12

## TL;DR

This paper introduces an AI-based app to improve the management of patients on blood-thinning medication, aiming to reduce healthcare costs and improve outcomes.

## Contribution

The novel contribution is the development and implementation of the AIto-Control app for managing vitamin K antagonist therapy using AI and ML.

## Key findings

- The AIto-Control app is expected to reduce healthcare costs by decreasing primary care visits and hospital admissions.
- Advanced practice nurses will play a key role in supervising app-based monitoring and patient education.
- The app aims to ease the workload on primary care and hospital services.

## Abstract

Background: Vitamin K antagonist oral anticoagulant (VKA) therapy, using warfarin or acenocoumarol in our health system, is indicated, according to clinical guidelines, for the prophylaxis of thromboembolic events. In Málaga, the VKA patient management program currently includes a total of 856 patients. Hypothesis: The use of an AI-based application can enhance treatment adherence among VKA patients participating in self-monitoring and self-management programs. Furthermore, it can support the comprehensive implementation of the system, leading to reduced costs and fewer interventions for anticoagulated patients. Methods: The study will be conducted in several phases. The first phase involves the development of the application and the integration of Artificial Intelligence (AI) and Machine Learning (ML) algorithms. The second phase includes preliminary testing and validation of the developed application. The third phase consists of full implementation, along with an assessment of user-identified needs and potential quality improvements. Expected Results: The implementation of the AIto-Control app is expected to reduce healthcare-related costs by decreasing primary care visits and hospital admissions due to thromboembolic or bleeding events. Additionally, it aims to ease the workload on both primary care and hospital services. These outcomes will be achieved through the involvement of advanced practice nurses who will supervise app-based monitoring and patient education.

## Linked entities

- **Chemicals:** warfarin (PubChem CID 54678486), acenocoumarol (PubChem CID 54676537)

## Full-text entities

- **Diseases:** thromboembolic (MESH:D013923), bleeding (MESH:D006470)
- **Chemicals:** Vitamin K (MESH:D014812), acenocoumarol (MESH:D000074), warfarin (MESH:D014859)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12565263/full.md

## Figures

3 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12565263/full.md

## References

34 references — full list in the complete paper: https://tomesphere.com/paper/PMC12565263/full.md

---
Source: https://tomesphere.com/paper/PMC12565263